NEW YORK–(COMMERCIAL THREAD)–The Graduate Institute of Medicine (PIM), which accredits more than 2,500 training activities for healthcare professionals every year, e VieCurea cancer care company with a powerful clinical decision support platform, is pleased to announce a new partnership designed to offer continuing medical education (CME) to multidisciplinary cancer care teams using the VieCure platform.
The Accreditation Council for Continuing Medical Education (ACCME) defines an Internet research and learning activity as an activity in which a physician engages in self-paced online learning about topics relevant to his or her clinical practice from a database whose content has been vetted by an accredited provider of ECM. Using this model, users of the VieCure platform will be able to claim CME credit to research new and emerging therapies for cancer patients.
Next-generation sequencing (NGS), which identifies the genomic drivers of a patient’s disease, is increasingly driving decision-making in cancer care. NGS has the potential to deliver the right care to the right patient at the right time, resulting in the kind of response expected from such a precise and personalized approach to medicine. However, there are barriers to achieving optimal outcomes based on NGS technology, including the inability to properly integrate data into the electronic health record and respond appropriately to NGS outcomes, across the continuum of cancer care. Additionally, the wealth of patient-specific data available to clinicians with NGS means that individual providers are challenged to integrate it effectively. The VieCure Platform, a next-generation AI-enabled clinical decision support tool, translates this data for busy providers.
“Cancer centers across the United States are moving away from reliance on the traditional use of cancer chemotherapy, radiation, and surgery and are in favor of sequencing patients at the time of diagnosis,” said Dr. Fred Ashbury, Chief Scientific Officer, at VieCure. “Using VieCure, they create personalized treatment plans that incorporate the latest immunotherapies and targeted treatments.”
CME’s offering to users of the VieCure platform through the Internet research and learning model recognizes the importance of artificial intelligence and other digital tools that are increasingly available to enhance the clinical and educational experience for healthcare professionals.
“By interacting with digital tools like the VieCure platform, busy clinicians are able to learn smarter and faster,” said Whitney Faler, director of accreditation and outcomes for PIM. “Awarding research credit makes perfect sense and is increasingly being adopted by savvy education planners and the students they aim to advocate.”
Starting January 2023, VieCure users will be able to earn 0.5 AMA PRA Category 1 Credit™ for every Internet research and learning session they perform.
About the Postgraduate Institute of Medicine
The Postgraduate Institute for Medicine (PIM) has been providing reliable independent continuing education for healthcare professionals since 1979 and is a recognized leader for jointly delivered continuing education activities. PIM is nationally accredited to certify education and issue continuing education credits to an interprofessional or multidisciplinary audience of students, including physicians, physician assistants, registered nurses, nurses, pharmacists, social workers, psychologists, dentists, optometrists, healthcare managers , registered dietitians, addiction counselors and clinical laboratory professionals. We specialize in accreditation through joint vendors as well as outcome measurement, grant solicitation and management, marketing and e-learning platform support through www.cmeuniversity.com.
VieCure has developed a proprietary AI software platform in combination with a clinical inference engine and decision support system at the point of care in oncology. The VieCure™ platform combines the latest clinical insights with patient data to help clinicians generate personalized treatment plans and better manage a patient’s treatment during cancer diagnosis, therapy, and ongoing follow-up care . VieCure was launched in 2015 and has contracts with leading community cancer centers such as the Center for Cancer and Blood Disorders (Fort Worth, Texas), Alabama Cancer Care (Tuscaloosa, Alabama), Clermont Oncology (Clermont, Florida), and many others including the American Oncology Network. The VieCure network of contracted cancer centers now includes more than 100 locations throughout the United States, the Bahamas and Antigua. Active rollout of the VieCure platform is underway at network locations across the United States. For more information, visit viecure.com and connect with VieCure on LinkedIn, Facebook and YouTube.